Table 3.
ALS clinical characteristics of the Discovery and Validation cohorts.
| Discovery cohort (N = 50) | Validation cohort (N = 8) | |
|---|---|---|
| Gender | ||
| Male (N, (%)) | 32 (64) | 5 (63) |
| Female (N, (%)) | 18 (36) | 3 (37) |
| Ethnicity | ||
| Non-Hispanic or Latino | 47 | N/A |
| Hispanic, Latino | 1 | N/A |
| Unknown/not reported | 2 | N/A |
| Race | ||
| White (N, (%)) | 45 (90) | N/A |
| Black (N, (%)) | 2 (4) | N/A |
| Unknown/not reported (N, (%)) | 3 (6) | N/A |
| ALS type | ||
| Sporadic (N, (%)) | 42 (84) | 6 (75) |
| Familial (N, (%)) | 8 (16) | 2 (25) |
| Age at diagnosis (Average, (SD)) | 53.4 (9.7) | 54.9 (11.9) |
| Disease duration (Average, (SD)) | 15.6 (20.4) | 11.0 (7.9) |
| ALSFRS-R (Average, (SD)) | 35.9 (8.1)⁎ | 36.4 (7.7) |
N/A = Not Available.
⁎
ALSFRS-R scores were available for 14 of the 50 patients in the Discovery cohort.